ReachMD

Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic Explore selection, sequencing & safety strategies for continuous vs fixed-duration therapies in CLL/SLL, including emerging BTK- and BCL2-directed approaches. Complimentary lunch will be provided. Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic close

Key Takeaways Across more than 1,000 patients undergoing brain tumor surgery at four Chinese centers, early postoperative pneumonia occurred within 7 days in part of the cohort. A logistic regression model using routine perioperative variables was selected after comparison with other algorithms and remained discriminative in prospective testing. Performance stayed consistent across three outside centers, with sensitivity ranging from 75.8% to 96.2% and specificity from 82.3% to 86.6%.

Key Takeaways In a tertiary rheumatology cohort from Türkiye, 40% of reassessed patients with newly diagnosed primary Sjögren disease were classified as low adherence during follow-up. Baseline sociodemographic and clinical characteristics did not distinguish patients with low adherence from those with high adherence. Disease activity, Sjögren symptom burden, fatigue, psychological symptoms, function, and health-related quality of life were broadly similar across adherence categories over time.

Key Takeaways Lower-body positive pressure treadmill running in healthy young men left some neural adjustments incomplete at the end of the first unweighting transition. Several unweighting adjustments were completed sooner during the second exposure, a pattern the authors interpreted as savings. Reloading back to full body weight was associated with completion of neural adjustments by the end of the transition in both runs.

Key Takeaways In a pooled randomized setting spanning 35 trials, a statistically significant atrial fibrillation signal was reported only among participants at high cardiovascular risk receiving more than 1500 mg/day of EPA/DHA. That high-risk, high-dose subgroup showed an absolute atrial fibrillation risk difference of 0.8%. Lower-dose EPA/DHA did not appear to increase atrial fibrillation risk, including in high-risk populations.

Key Takeaways In a Dutch prospective NMIBC cohort of more than 1,000 patients, higher fruit and vegetable intake 3 months after diagnosis was associated with lower first recurrence risk. Increases in total fruit and vegetable intake from before diagnosis to 3 months after diagnosis were also associated with lower first recurrence risk. Prediagnosis intake and both dietary and plasma carotenoids were not associated with recurrence or progression outcomes.

Key Takeaways Patients with peanut allergy plus at least two additional food allergies in OUTMATCH stage 2 had higher overall treatment success with continued omalizumab than with omalizumab-facilitated multiallergen oral immunotherapy. Completion was more common with omalizumab than with multiallergen oral immunotherapy, at 88% versus 51%, and adverse events accounted for more discontinuations in the oral immunotherapy arm.

Key Takeaways Among working-age adults on sick leave for chronic nonmalignant pain recruited from Swedish primary care, remote PCC added to usual care was associated with a significant 6-month advantage on the prespecified composite of self-efficacy and sick leave. Deterioration was less common with the intervention, while stability over follow-up was more common than with usual care alone. Self-efficacy differed significantly at 6 months, and sick leave differed significantly at 3 months.

Key Takeaways Among 2,584 critically ill adults with cerebrovascular disease, all-cause mortality was 18.7% at 30 days, 23.2% at 90 days, and 28.9% at 365 days. After full adjustment, the admission TyG index was not significantly associated with 30-day or 365-day mortality in the overall cohort and showed only a borderline association at 90 days. Diabetes status significantly modified the TyG-mortality relationship across all three follow-up windows.

Botulinum toxin A (BTX-A) may offer dermatologists a way to address the functional, therapeutic, and aesthetic manifestations of facial paralysis within a single treatment framework, a recent review suggested.d The authors conducted a narrative review of PubMed-indexed literature examining aesthetic and therapeutic applications of BTX-A in facial paralysis and focused on 3 domains: facial asymmetry, functional impairment, and neuromuscular dysregulation.